Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways and therapeutic options without systematic methodology or primary human data.
PubMed 38172476 · doi:10.1007/s13679-023-00531-2
What was done
This is a narrative review summarizing the pathophysiological interactions between the hypothalamic-pituitary-ovarian (H-P-O) axis, visceral adiposity, and chronic inflammation in polycystic ovary syndrome (PCOS), alongside an overview of nutraceutical and pharmacological management strategies.
What was found
No quantitative findings, sample sizes, or effect estimates are reported in the abstract. The authors describe a self-feeding cycle in PCOS wherein elevated androgens promote visceral fat deposition, driving insulin resistance and hyperinsulinemia, which in turn further stimulates ovarian and adrenal androgen production. The abstract notes that women with PCOS have greater adipose tissue and reduced lean mass compared to healthy women regardless of age and body mass index.
Why it matters
The paper outlines the bidirectional crosstalk between neuroendocrine disruption and visceral adiposity in PCOS, supporting multimodal management addressing metabolic and inflammatory drivers alongside standard hormonal care.
Limits
This is a narrative review with no systematic search methodology, meta-analysis, or primary human data reported. Specific nutraceutical and pharmacological agents, dosages, and comparative clinical efficacy metrics are not detailed in the abstract.